Esomeprazole – S-isomer of omeprazole with more favorable pharmacological properties and stronger pharmacodynamic effect
Drug profileGastroent Hepatol 2018; 72(2): 179–181. doi:10.14735/amgh2018179
Literaturepdf Milan LukášVSL#3 – the first highly concentrated therapeutic probiotic with multiple bacterial strains and a proven therapeutic efficacy
Drug profileGastroent Hepatol 2018; 72(1): 85–86. doi:10.14735/amgh201885
Literaturepdf Luděk HrdličkaMeteospasmyl – a fixed combination of alverine citrate and simethicone in the treatment of digestive tract functional disorders
Drug profileGastroent Hepatol 2017; 71(5): 455–456. doi:10.14735/amgh2017455
pdf Milan LukášRemsima® – the first biosimilar infliximab CT-P13
Drug profileGastroent Hepatol 2017; 71(4): 363–364. doi:10.14735/amgh2017363
Literaturepdf Milan LukášRifaximin
Drug profileGastroent Hepatol 2017; 71(3): 271–272. doi:10.14735/amgh2017271
Literaturepdf Martin BortlíkUstekinumab – a new biological therapy for patients with Crohn’s disease
Drug profileGastroent Hepatol 2017; 71(2): 178–180. doi:10.14735/amgh2017178
Literaturepdf Milan LukášPicoprep® – a clearing agent with a new dosing schedule
Drug profileGastroent Hepatol 2017; 71(2): 175–176. doi:10.14735/amgh2017175
Literaturepdf Milan LukášGinkor Fort® with ginkgo biloba extract
Drug profileGastroent Hepatol 2017; 71(1): 87–88. doi:10.14735/amgh201787
Literaturepdf Milan LukášCombination of sofosbuvir and velpatasvir (Epclusa®)
Drug profileGastroent Hepatol 2016; 70(6): 553–554. doi:10.14735/amgh2016553
pdf Petr UrbánekUrsodeoxycholic acid
Drug profileGastroent Hepatol 2016; 70(5): 457–462. doi:10.14735/amgh2016457
Literaturepdf Jan Juřica